https://www.selleckchem.com/pr....oducts/vx803-m4344.h
ents during the last 20 years only applies for standard-risk patients, while high-risk MM patients still are doing poorly, indicating that the novel drugs developed during this time are preferentially effective in standard-risk patients. New treatment modalities like CAR-T cells, CAR-NK cells, and/or bispecific antibodies should be tried in clinical studies early in the course of the disease, especially in patients with high-risk cytogenetics.Abiotic stress resistance traits may be especially crucial for sustainable production of bi
Like
Comment
Share
